1. Xtant Medical launches nanOss Strata™, enhancing synthetic bone graft technology. 2. Strata™ mimics human bone, improving osteoconductivity and cellular activity. 3. The product aims to boost surgical outcomes for orthopedic conditions. 4. CEO Sean Browne emphasizes commitment to innovation in regenerative medicine. 5. Strata™ is available through Xtant's nationwide distribution network.
FAQ
Why Bullish?
The launch of nanOss Strata could enhance XTNT's product offerings, potentially increasing sales and market share, similar to successful previous product introductions in the orthobiologics market.
How important is it?
The introduction of a next-generation product is significant for XTNT’s growth and competitive positioning in the medical technology field.
Why Short Term?
New product launches generally have immediate effects on stock prices as markets react to potential revenue growth.
Xtant Medical Announces Commercial Launch of Next-Generation nanOss Strata™ Synthetic Bone Graft
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has officially unveiled its innovative synthetic bone graft in the nanOss line, aimed at enhancing surgical outcomes in orthopedic procedures.
Overview of nanOss Strata™
The newly launched nanOss Strata™ synthetic bone graft is designed to closely replicate the structure of human bone while maximizing the graft's surface area. This cutting-edge product aims to improve osteoconductivity and stimulate cellular activity, fostering better integration during the healing process.
Manufactured from hydroxycarbonapatite (HCA), a material with greater solubility than traditional hydroxyapatite (HA), nanOss Strata enhances the bioactivity of bone grafts. This allows for optimized integration and remodeling with surrounding bone tissue, which is crucial for effective recovery.
Product Features and Variants
nanOss Strata™ is available in two distinct forms:
- Compression-resistant preformed strips
- Prehydrated moldable grafts
Both options are sterile, moldable, and designed for rapid absorption of blood and biologic fluids, making them suitable for various surgical applications.
Expert Insights on Innovation
Sean Browne, President and CEO of Xtant Medical, highlighted the significance of nanOss Strata in the company's portfolio: "By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients."
Distribution and Availability
nanOss Strata™ is now available across Xtant Medical's nationwide distribution network, marking a vital step in making this advanced synthetic bone graft accessible to healthcare providers throughout the country.
About Xtant Medical Holdings, Inc.
Xtant Medical is dedicated to honoring the gift of human tissue donation to enhance patient care. The company, listed as XTNT, is recognized for its development and commercialization of a diverse range of orthobiologics that cater to chronic and surgical wound care, sports medicine, and spinal implant systems.
Cautionary Statements
This announcement contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause actual results to differ significantly from projected outcomes. Investors should review Xtant Medical's filings with the Securities and Exchange Commission (SEC) for a comprehensive discussion of these risks.